Cracking the Code of Neurodegeneration

Digital drawing of progressive degeneration in a neuronal network: blue represents healthy neurons, while orange and red represent the protein NPTX2. Yellow shows the toxic aggregation of the protein TDP-43.
(c) Niklas Bargenda

New Model Identifies Potential Therapeutic Target.

Scientists at the University of Zurich have developed an innovative neural cell culture model, shedding light on the intricate mechanisms underlying neurodegeneration. Their research pinpointed a misbehaving protein as a promising therapeutic target in the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Neurodegenerative diseases cause some of the neurons in our brains to die, resulting in different symptoms depending on the brain region affected. In amyotrophic lateral sclerosis (ALS), neurons in the motor cortex and spinal cord degenerate, leading to paralysis. In frontotemporal dementia (FTD), on the other hand, neurons located in the parts of the brain involved in cognition, language and personality are affected.

Both ALS and FTD are relentlessly progressive diseases and effective treatments are still lacking. As the population ages, the prevalence of age-related neurodegenerative diseases such as ALS and FTD is expected to increase.

Despite the identification of the aberrant accumulation of a protein called TDP-43 in neurons in the central nervous system as a common factor in the vast majority of ALS and about half of FTD patients, the underlying cellular mechanisms driving neurodegeneration remain largely unknown.

Flexible, durable, reproducible: ideal cell culture model for ALS and FTD research

In their study, first author Marian Hruska-Plochan and corresponding author Magdalini Polymenidou of the Department of Quantitative Biomedicine at the University of Zurich developed a novel neural cell culture model that replicates the aberrant behavior of TDP-43 in neurons. Using this model, they discovered a toxic increase in the protein NPTX2, suggesting it as a potential therapeutic target for ALS and FTD.
To mimic neurodegeneration, Marian Hruska-Plochan developed a new cell culture model called “iNets,” derived from human induced pluripotent stem cells. These cells, originated from skin cells and reprogrammed to a very early, undifferentiated stage in the laboratory, serve as a source for developing many different, desired cell types. iNets are a network of interconnected neurons and their supporting cells growing in multiple layers in a dish.

The cultures lasted exceptionally long – up to a year – and were easily reproduced. “The robustness of aging iNets allows us to perform experiments that would not have been possible otherwise,” says Hruska-Plochan. “And the flexibility of the model makes it suitable for a wide range of experimental methodologies.” As a case in point, the iNets cell cultures provided the ideal model to investigate the progression from TDP-43 dysfunction to neurodegeneration.

How protein dysfunction leads to neurodegeneration

Employing the iNets model, the researchers identified a toxic accumulation of NPTX2, a protein normally secreted by neurons through synapses, as the missing link between TDP-43 misbehavior and neuronal death. To validate their hypothesis, they examined brain tissue from deceased ALS and FTD patients and indeed found that, also in patients, NPTX2 accumulated in cells containing abnormal TDP-43. This means that the iNets culture model accurately predicted ALS and FTD patient pathology.

In additional experiments in the iNets model, the researchers tested whether NPTX2 could be a target for drug design to treat ALS and FTD. The team engineered a setup in which they lowered the levels of NPTX2 while neurons were suffering from TDP-43 misbehavior. They found that keeping NPTX2 levels low counteracted neurodegeneration in the iNets neurons. Therefore, drugs that reduce the amount of the protein NPTX2 have potential as a therapeutic strategy to halt neurodegeneration in ALS and FTD patients.

Magdalini Polymenidou sees great promise in this discovery: “We still have a long way to go before we can bring this to the patients, but the discovery of NPTX2 gives us a clear shot of developing a therapeutic that acts at the core of the disease,” she said. “In conjunction with two additional targets recently identified by other research teams, it is conceivable that anti-NPTX2 agents could emerge as a key component of combination therapies for ALS and FTD in the future,” she added.

Wissenschaftliche Ansprechpartner:

Prof. Dr. Magdalini Polymenidou
Professor of Biomedicine
Department of Quantitative Biomedicine
University of Zurich
Phone: +41 44 635 31 06
E-mail: magdalini.polymenidou@uzh.ch

Originalpublikation:

Marian Hruska-Plochan, Vera I. Wiersma, Katharina M. Betz, et al., Magdalini Polymenidou. A model of human neural networks reveals NPTX2 pathology in ALS and FTLD. Nature (2024). Doi.org/10.1038/s41586-024-07042-7

Weitere Informationen:

https://news.uzh.ch/de/articles/media/2024/Neurodegeneration Media Release

Media Contact

Barbara Simpson Kommunikation
Universität Zürich

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

EEG ad tDCS chould serve as the basis of therapeutic strategies to combat newrological disorders. Image Credit: Institute of Science Tokyo

Using Electroencephalography to Improve Language Disorder Treatments

Researchers work towards an inexpensive and portable solution for treating aphasia  Electroencephalography (EEG) may offer a more accessible alternative to functional magnetic resonance imaging (fMRI) for guiding transcranial direct current…

The BioSCape team is poctured with NASA and South African aircraft. Image Credit: Jeremey Shelton/Fishwater Films

Measuring Life on Earth from Space: A Global Research Project

Measurements and data collected from space can be used to better understand life on Earth. An ambitious, multinational research project funded by NASA and co-led by UC Merced civil and…

NEJM study finds patients with blockages in medium-sized vessels in the brain who had endovascular treatment did not do any better and did not see any improvement compared to patients who had the standard of care. Dr. Michael Hill, MD, Dr. Mayank Goyal, MD, PhD (right). Image Credit: Riley Brandt, University of Calgary

Best Approach for Stroke in Medium-Sized Blood Vessels Identified

Calgary’s Stroke Program advancing science to improve care, treatment and outcomes for patients  University of Calgary’s Hotchkiss Brain Institute researchers with the Calgary Stroke Program at Foothills Medical Centre revolutionized…